Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | PRGN-3006 |
Trade Name | |
Synonyms | PRGN 3006|PRGN3006 |
Drug Descriptions |
PRGN-3006 is a cell-based therapy comprising autologous T-cells engineered to express membrane-bound IL15 and a chimeric antigen receptor (CAR) that recognizes CD33 as well as a kill switch, potentially resulting in increased anti-tumor response against CD33-expressing tumor cells (Blood (2019) 134 (Supplement_1): 2660). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C160847 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Cyclophosphamide + Fludarabine + PRGN-3006 | Cyclophosphamide Fludarabine PRGN-3006 | 0 | 0 |
PRGN-3006 | PRGN-3006 | 0 | 1 |